Related by context. All words. (Click for frequent words.) 87 Clinical Oncology Annual Meeting 84 Clinical Oncology ASCO 82 Hematology Annual Meeting 81 Hematology ASH Annual Meeting 80 Hematology ASH 78 Hematology Meeting 74 Cancers Symposium 74 Clinical Oncologists 73 Nephrology Renal Week 73 Clinical Oncology 73 Hematology ASH Meeting 73 ASCO Annual Meeting 72 Radiation Oncology ASTRO 71 Gene Therapy ASGT 71 Connective Tissue Oncology 69 AACR NCI EORTC 69 ASH Annual Meeting 69 nd Annual Meeting 69 Gastrointestinal Cancers Symposium 69 Medical Oncology ESMO 69 Digestive Disease Week DDW 69 Annual Scientific Sessions 68 Human Genetics ASHG 68 Society CTOS 68 Digestive Disease Week 68 Neurology AAN 67 Microbiology ASM 67 Therapeutic Radiology 67 Clinical Oncology ASCO Gastrointestinal 67 Breast Surgeons ASBS 67 Scientific Sessions 67 Clinical Oncology Gastrointestinal Cancers 67 EORTC NCI AACR 67 AHA Scientific Sessions 66 Pharmaceutical Scientists AAPS 66 st Annual Meeting 66 Mass Spectrometry ASMS 66 Hypertension ASH 66 Oncology ASTRO 66 Interventional Radiology SIR 65 American Roentgen Ray 65 AACR #nd Annual Meeting 65 Arteriosclerosis Thrombosis 65 Genitourinary Cancers Symposium 65 Cancer iSBTc 65 Rheumatology ACR Annual 65 #th Annual Interscience 65 ASCO GI 65 Biological Therapy 65 Anesthesiologists Annual Meeting 64 AACR #st Annual Meeting 64 AACR San Antonio 64 Neurology Annual Meeting 64 Chemotherapy ICAAC 64 annual Transcatheter Cardiovascular 64 Anesthesiologists ASA Annual Meeting 64 ASCO Genitourinary Cancers Symposium 64 Nephrology ASN Renal 64 Liver EASL 64 Cell Biology ASCB 63 Scientific Session 63 Hematology 63 Nephrology Annual Meeting 63 Reproductive Medicine ASRM 63 Stem Cell Research ISSCR 63 Molecular Targets 63 Neuro Oncology SNO 63 EORTC NCI AACR Symposium 63 Clinical Chemistry AACC 63 Breast Surgeons 63 Endocrine Society ENDO 63 Anesthesiologists ASA 63 #st Annual Meeting 63 Liver Diseases AASLD 63 ICAAC 63 Rheumatology Annual 63 Scientific Meeting 63 AUA Annual Meeting 62 Retina Specialists 62 Mineral Research ASBMR 62 Vascular Biology ATVB 62 ECTRIMS 62 Therapeutic Radiation 62 System Pharmacists ASHP 62 AACR Annual Meeting 62 Therapeutics TCT scientific 62 Late Breaker 62 Diabetes EASD 62 CTRC AACR San Antonio 62 League Against Rheumatism 61 ADA Scientific Sessions 61 Gynecologic Investigation 61 Cardiology ESC Congress 61 Transcatheter Cardiovascular Therapeutics TCT 61 Ophthalmology AAO 61 Antimicrobial Agents 61 Maternal Fetal Medicine SMFM 61 ongoing Phase 1b 61 Alzheimer Disease ICAD 61 Gynecologic Oncologists 60 Annual ICAAC 60 AACR Meeting 60 Echocardiography ASE 60 AASLD 60 ASCO 60 AACR symposium 60 San Antonio Breast Cancer 60 Endocrine Society Annual Meeting 60 AACR 60 Digestive Diseases Week 60 Heart Failure Society 60 AAO HNSF Annual Meeting 60 Liver Disease AASLD 60 Surgical Oncology SSO 60 Endocrine Society #nd 60 Cardiology ESC 60 Breast Cancer Symposium SABCS 60 Cellular Therapy ISCT 60 ASCO GU 59 Breast Cancer Symposium 59 ASCO Breast Cancer 59 Controlled Release 59 Neck Surgery Foundation 59 Annual Transcatheter Cardiovascular 59 Gastrointestinal Endoscopy 59 Cardiovascular Anesthesiologists 59 & OTO EXPO 59 #nd Annual Meeting 59 SABCS 59 Liver Diseases 59 Prostate Cancer Symposium 59 American Thoracic Society 59 ICAAC IDSA 59 Pediatric Academic Societies PAS 59 Thoracic Surgeons STS 59 Healthcare Epidemiology 59 Retina Specialists ASRS 59 #nd EORTC NCI 59 Hypertension ESH 59 Neurological Surgeons AANS 58 Endocrine Society #st 58 Nephrology ASN 58 Thoracic Surgeons 58 Therapeutics TCT 58 CROI 58 ASGT 58 Cardiology ACC 58 ECCMID 58 Gastroenterology ACG Annual 58 Gastrointestinal Endoscopy ASGE 58 Transcatheter Cardiovascular Therapeutics 58 Neuropsychopharmacology 58 Gastroenterology ACG 58 Ophthalmology ARVO 58 Experimental Biology 58 Medicine SIIM 58 Interventions SCAI 57 ENDO 57 PROVENGE sipuleucel T 57 Pediatric Academic Societies 57 Cardiology Scientific Sessions 57 Thoracic Surgery AATS 57 Clinical Oncologists ASCO 57 EORTC NCI 57 PEG SN# 57 Midyear Clinical Meeting 57 Rheumatology ACR 57 #th Interscience Conference 57 Clinical Virology Symposium 57 evaluating tivozanib 57 Endovascular Therapy ISET 57 Gemzar ® 57 metaglidasen 57 Clinical Pathology ASCP 57 CRLX# 57 EASL 57 Menopause Society NAMS 57 novel VDA molecule 57 Hsp# Inhibitor 57 Clinical Microbiology 57 Plastic Surgeons ASPS Plastic 57 Clinical Endocrinologists AACE 57 Gynecologic Oncologists SGO 57 Roentgenology 57 Vascular Annual Meeting 57 Minimally Invasive Cardiothoracic Surgery 57 Combination REOLYSIN R 57 proteasome inhibitor 57 Nephrology JASN 57 Amrubicin 57 PROSTVAC TM 57 ISPOR 56 System Pharmacists Midyear 56 ORAL Sync 56 Immunology Annual Meeting 56 Investigative Dermatology 56 AASLD Meeting 56 Clinical Chemistry 56 Opportunistic Infections CROI 56 Lung Transplantation 56 Carfilzomib 56 Dermatology AAD 56 CCX# 56 Advanced Neuroendocrine Tumors 56 Applied Spectroscopy 56 alvespimycin 56 ASBMR 56 AACR NCI EORTC Molecular 56 delafloxacin 56 Symposium SABCS 56 CTAP# Capsules 56 KRN# 56 America RSNA 56 Phase #/#a trial 56 Hyperthermic Oncology ESHO 56 Pediatric Academic Society 56 American Urological Association 56 ESMO 56 vascular disrupting agent 56 Orthopedic Surgeons AAOS 56 INCB# [001] 56 UEGW 56 rALLy trial 56 Transplantation AST 56 Toxicology SOT 56 Cervical Pathology 56 European CanCer Organisation ECCO 56 Phase 2a clinical 56 TACI Ig 56 Urology EAU 56 cetuximab Erbitux 56 Radiological Society 55 histone deacetylase HDAC inhibitor 55 sorafenib tablets 55 Chemophase 55 Experimental Biology Annual Meeting 55 phase IIa clinical 55 ACR ARHP Annual 55 Interscience Conference 55 Nephrology CJASN 55 Cystic Fibrosis Conference NACFC 55 fosbretabulin 55 Remote Sensing ASPRS 55 Brentuximab Vedotin SGN 55 anticancer compound 55 Perifosine 55 ECCO ESMO 55 Cloretazine ® 55 ACUITY trial 55 chemotherapy gemcitabine 55 Endoscopic Surgeons 55 AAN Annual Meeting 55 International Papillomavirus 55 Biologic Therapy 55 SCCHN 55 preclinical efficacy 55 Cachexia 55 oral rivaroxaban 55 enzastaurin 55 EuroPCR 55 Investigative Pathology 55 Bariatric Surgery ASBS 55 CYT# potent vascular disrupting 55 BRIM2 55 dose escalation clinical 55 ARVO 55 INSPIRE Trial Phase III 55 Randomized Phase 55 HCV SPRINT 55 SCAI Annual 55 BiTE R 55 oral proteasome inhibitor 55 Solorel TM 55 Association Executives ASAE 55 ASTRO Annual Meeting 54 perifosine 54 Doxil ® 54 American Gastrointestinal Endoscopic 54 Transplant Surgeons ASTS 54 APOPTONE 54 ToGA 54 ELACYT 54 SAEM Annual Meeting 54 AABB Annual Meeting 54 Announces Poster Presentations 54 RGB # 54 Phase 1b trial 54 Ophthalmology Annual Meeting 54 Endoscopic Surgeons SAGES 54 ON #.Na 54 perifosine KRX 54 ABRF 54 ImmunoVEX HSV2 54 maximally tolerated dose 54 Therapeutic Radiation Oncology 54 huC# DM4 54 Malignant Lymphoma 54 #rd Annual CTRC 54 Chemical Society 54 Arch Surg 54 CR# vcMMAE 54 Canaccord Adams Hepatitis C 54 pertuzumab 54 oral ridaforolimus 54 Talabostat 54 ganetespib 54 Phase Ib study 54 Annual Meeting 54 GVAX ® 54 vidofludimus 54 assessing T DM1 54 Tanespimycin 54 Epilepsy Society 54 Molecular Medicine Tri 54 recurrent malignant glioma 54 Phase 2a trial 54 Aflibercept 54 BIOCOM Investor Conference 54 Antimicrobial Chemotherapy 54 International Neuropsychological Society 54 Pirfenidone 54 Clinical Trial Results 54 orally administered inhibitor 54 OncoVEX GM CSF 54 Chicago Multidisciplinary Symposium 54 www.aacr.org 54 IL# PE#QQR 54 taxane resistant 54 Phase III ADT 54 TG MV 54 Inflammatory Bowel Diseases 54 midstage clinical 54 Biomolecular Sciences SBS 54 Cardiovascular Angiography 54 SAWC WHS 54 metastatic HRPC 54 & Immunology AAAAI 54 fidaxomicin Phase 3 54 rALLy clinical trial 54 DDW ® 54 trastuzumab DM1 T DM1 54 Cloretazine R 54 radezolid 53 ACR ARHP 53 Endovascular Therapy 53 Nasdaq ENZN 53 Neurological Surgeons Annual Meeting 53 Hedgehog Pathway Inhibitor 53 OXi# 53 seliciclib CYC# 53 Poster Discussion 53 NASDAQ CXSP announced 53 oral prodrug 53 mitogen activated ERK kinase 53 BIO InvestorForum 53 ASH Abstract # 53 Inc. Nasdaq OPTR 53 CLARITY study 53 CA4P 53 SUCCEED trial 53 Phase Ib II 53 Biomolecular Sciences 53 obatoclax 53 Phase 2a Clinical Trial 53 Retroviruses 53 Clinical Oncology JCO 53 Paediatric Oncology SIOP 53 histone deacetylase inhibitor 53 IRX 2 53 Colposcopy 53 depsipeptide 53 atacicept 53 Rheumatology Annual Meeting 53 Phase Ib clinical 53 metastatic castration resistant 53 Jupiter Tequesta Orchid 53 HuMax CD4 53 PERSEUS 53 American Psychosomatic Society 53 Pain Medicine AAPM 53 phase IIb clinical 53 Radiology Imaging Network ACRIN 53 teriflunomide 53 AACR IASLC Joint 53 Phase #b/#a clinical 53 ® DDW 53 Azedra 53 pralatrexate 53 OvaRex R 53 MOZOBIL 53 AA Amyloidosis 53 Golf Course Architects ASGCA 53 FDA Oncologic Drugs 53 HCV NS5B polymerase 53 www.asco.org 53 ERA EDTA 53 Experimental Biology FASEB 53 Xanafide 53 Gastrointestinal Cancer 53 non nucleoside inhibitor 53 neratinib 53 abstracts summarizing 53 AACR Frontiers 53 compound AEZS 53 Related Disorders ICAD 53 Heart Rhythm 53 Neuro Oncology 53 Phase 2b Clinical Trial 53 Oncology Nursing 53 phase IIa 53 Pharmacoeconomics 53 rivaroxaban Xarelto 53 Annual Interscience Conference 53 Neuropsychopharmacology ACNP 53 AVERROES 53 Preclinical Study 53 HCV polymerase inhibitors 53 cediranib 53 lexidronam injection 53 EULAR Annual 53 FOLFOX6 chemotherapy regimen 53 CALGB # [002] 53 Clinical Trials Update 53 oral JAK1 53 ENDEAVOR III 53 HDL Selective Delipidation 53 Chronic Lymphocytic Leukemia CLL 53 Antiviral Research 53 metastatic hormone refractory 53 CEQ# 53 Equine Practitioners Convention 53 Professional Sleep Societies 53 International Myeloma Workshop 53 Diabetic Macular Edema 53 Outcomes Research ISPOR 53 ZYBRESTAT 53 Phase 2b trial 53 YONDELIS 53 HyQ 53 AACR EORTC NCI 53 PLK1 SNALP 53 PSN# [002] 53 LymphoStat B 53 Guanilib 53 forodesine 53 EULAR 53 DU #b 53 USpella 53 TASKi2 53 axitinib 53 HuMax EGFr 52 recurrent glioma 52 Exploration Geophysicists SEG 52 Nexavar sorafenib 52 NASDAQ SLXP today 52 Clinical Dermatology 52 FOLOTYN ® 52 Medicine AAPM 52 Hygiene ASTMH 52 Bortezomib 52 Interventional Radiology 52 CRMD# 52 EOquin TM 52 phase 2a 52 refractory multiple myeloma 52 MGd 52 Personalized Immunotherapy 52 Sym# 52 Spine Arthroplasty Society 52 Cancer Therapeutics 52 GRN#L 52 America HFSA 52 EGEN 52 ASCO Gastrointestinal Cancers Symposium 52 Metastatic Melanoma 52 OMP #M# 52 Dermatologic Surgery 52 Chest Physicians CHEST 52 Molecular Cancer 52 pan HDAC inhibitor 52 Nordic ACTI 52 Microplasmin 52 bazedoxifene conjugated estrogens 52 AIR2 Trial 52 PANVAC VF 52 ZYBRESTAT fosbretabulin 52 PEGylated interferon beta 1a 52 docetaxel chemotherapy 52 Ambrisentan 52 Traficet EN 52 Physiology Regulatory Integrative 52 Spine Society 52 Panzem R 52 MTT S 52 Abstract # 52 Phase 2a 52 Refractive Surgery ASCRS 52 Immunologists 52 Neurology AAN Annual Meeting 52 TÎ ² 4 52 phase IIb study 52 Oak Brook Ill. RSNA.org 52 amrubicin 52 Cellular Therapy 52 BRIM3 52 EGS# 52 riociguat 52 Oral Fingolimod 52 Dermatologic Surgery ASDS 52 antibody MT# 52 Molecular Pathology AMP 52 NEUVENGE 52 preclinical pharmacokinetic 52 Cardiology Heart Failure 52 HepaSphere 52 Neurological Surgeons 52 Romidepsin 52 PCK# 52 BR.# 52 NAREIT Investor 52 Hand ASSH 52 PSMA ADC 52 COU AA 52 Phase 2a Study 52 oral FTY# 52 ASCO abstract 52 coronary stent merged 52 Ophthalmology ARVO Annual Meeting 52 PNP inhibitor 52 HQK 52 Natalizumab 52 sipuleucel T 52 Anticancer Drugs 52 R roscovitine 52 Diabetologia 52 Safinamide 52 galiximab 52 drug eluting stent DES 52 INCB# [002] 52 MEND CABG 52 LBH# 52 Gynecologic Cancer Society 52 sorafenib Nexavar 52 Chemotherapy ICAAC Infectious Diseases 52 Belimumab 52 Addiction Medicine ASAM 52 journal Antimicrobial Agents 52 Phase III ALLEGRO 52 Zybrestat 52 resistant ovarian cancer 52 Breaking Clinical Trials 52 RECORD1 52 LymphoStat B TM 52 ExTRACT TIMI 52 Targeted Anticancer Therapies 52 Chronic Lymphocytic Leukemia 52 PITTCON 52 Omacetaxine 52 ABCSG 52 mGluR5 negative 52 Bariatric Physicians ASBP 52 PXD# 51 CLEO QELS 51 AEG# 51 PROSTVAC VF 51 entinostat 51 Nuclear Cardiology 51 Reproductive Medicine specify 51 abnormal p# 51 elotuzumab 51 CBLC# 51 Urologic Oncology SUO 51 Annual BIO 51 Cell Transplant 51 Opportunistic Infections 51 Tolvaptan 51 Multiple Sclerosis ECTRIMS 51 aflibercept 51 registrational Phase 51 Abstract Number 51 Thoracic Oncology 51 Physiology Renal Physiology 51 dasatinib Sprycel 51 NASDAQ CYTK announced 51 Recurrent Chest Wall 51 CYPHER R Sirolimus eluting 51 Surgery ASLMS 51 Haemostasis ISTH 51 zanolimumab 51 Randomized Phase III 51 immunotherapeutic agent 51 Pivotal Clinical Trial 51 Canaccord Adams Musculoskeletal 51 Cloretazine R VNP#M 51 Aplidin 51 TLR antagonists 51 ALN VSP 51 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 51 Completes Patient Enrollment 51 anti amnesic 51 relapsed multiple myeloma 51 HIF PH inhibitors 51 Phase III AFFIRM 51 Preclinical Data 51 R lenalidomide 51 picoplatin 51 Cardiovascular Computed Tomography 51 selective kinase inhibitor 51 huN# DM1 51 Acquired Immune Deficiency Syndromes 51 RNAi Therapeutic 51 Aryplase 51 Urocortin 2 51 Archexin 51 PRNewswire FirstCall Amylin Pharmaceuticals 51 ZOLINZA 51 Vacuum Coaters 51 TXPO 51 PROTECT AF 51 Infectious Diseases ECCMID 51 alvimopan 51 Aesthetic Mesotherapy 51 PROSTASCINT R 51 EMBLEM TM 51 Marine Mammalogy 51 Zarnestra 51 Aplidin R 51 AAPS Annual Meeting 51 SPIRIT III 51 adecatumumab 51 ThermoDox ® clinical 51 International Cartilage Repair 51 Aesthetic Plastic Surgery ASAPS 51 entitled Synergistic 51 Rheumatology 51 Anti Infective Drugs 51 Trofex 51 Phase III psoriasis 51 Vascular Biology 51 JAK2 inhibitor 51 CIMZIA ™ 51 Healthcare Publication Editors 51 SPIRIT IV 51 mRCC 51 Integrative Oncology 51 ALN TTR 51 EVEREST II 51 Randomized Phase II 51 PRNewswire FirstCall Genta Incorporated 51 Dasatinib 51 Pemetrexed 51 Romiplostim 51 PERSEUS clinical program 51 GRNCM1 51 tasocitinib 51 BiTE antibody 51 HORIZONS AMI 51 Varespladib 51 Medical Oncology 51 recurrent GBM 51 Phase 2b 51 varespladib 51 randomized Phase III 51 Xelox 51 trabectedin 51 JAK1 51 Interventional Pain Physicians 51 Semafore Pharmaceuticals 51 Teriflunomide 51 essential thrombocythemia ET 51 ENMD # 51 aliskiren 51 Dermatology Physician Assistants 51 MDV# 51 MERLIN TIMI 51 J Clin Oncol 51 HORIZONS AMI trial 51 SYNTAX trial 51 hormone refractory metastatic prostate 51 ThermoDox R 51 Percutaneous Cardiovascular Interventions 51 preclinical 51 Cancer EORTC 51 Am J Epidemiol 51 CUSTOM III 51 novel histone deacetylase 51 Information Display SID 51 XL# SAR# 51 Prostate AdenoCarcinoma Treatment 51 AP# [003] 51 epigenetic therapies 51 Ovarian PLCO Cancer 51 iclaprim 51 Movement Disorder 51 Group RTOG 51 Cardiology 51 liposome injection 51 Rhinology 51 Phase 1b 51 Panzem R NCD 51 Zenvia Phase III 51 E CENP E 51 CUDC 51 atypical Hemolytic Uremic Syndrome 51 Nasdaq PCYC 51 voreloxin 51 Gleevec imatinib mesylate 51 Genasense ® 51 Plicera 51 Abstract Accepted 51 EXPAREL ™ 51 Cardiovascular Pharmacology 51 Glufosfamide 51 rALLy 51 Apoptone 50 Radiologic Technologists ASRT 50 Xcytrin R 50 Deforolimus 50 evaluating mipomersen 50 Gynecologic Laparoscopists 50 trial evaluating PRX# 50 targeting CD# 50 HER2 positive metastatic breast 50 cyclophilin inhibitors 50 Oncologic Drugs Advisory 50 Radiologic Society 50 multiple myeloma MM 50 Hepatology journal 50 pralatrexate injection folate analogue 50 Therapeutics Roundtable 50 Boceprevir 50 orally inhaled migraine 50 II Clinical Trial 50 Presents Preclinical 50 HGS ETR1 50 Elvitegravir 50 MEK inhibitor 50 HIMSS Healthcare 50 TTF Therapy 50 ASMS Conference 50 intravenous bisphosphonates 50 Elagolix 50 interferon gamma 1b 50 tolvaptan 50 CARE HF 50 NSTI Nanotech 50 potent anticancer 50 Imprime PGG ® 50 AS# amonafide L malate 50 Inc. Nasdaq VRUS 50 HCV RESPOND 2 50 Inc. Nasdaq IMGN 50 Rectal Surgeons 50 Oral Presentations 50 bortezomib Velcade 50 Nasdaq GNTA 50 Experimental Biology EB 50 BiTE ® 50 Paediatric Infectious Diseases 50 Malignant Mesothelioma 50 Endourology 50 Ocular Pharmacology 50 ENDEAVOR IV 50 PRNewswire FirstCall Ardea Biosciences 50 Edge STudy 50 relapsed refractory multiple myeloma 50 AGBT 50 Ceflatonin R 50 CombAT 50 Neoplasia 50 Plastics Engineers SPE 50 NovoTTF 50 placebo controlled clinical 50 Selective Cardiac Myosin 50 Arch Neurol 50 investigational immunotherapy 50 including eniluracil ADH 50 gemcitabine Gemzar 50 ASCO Prostate Cancer 50 HDL Mimetic Peptide 50 Nuclear Cardiology ASNC 50 decitabine 50 Global Healthcare Unplugged 50 Investor Luncheon 50 Advanced Renal Cell 50 Factor VIIa inhibitor 50 Vascular Surgery SVS 50 MLN# 50 alpha antagonist 50 Inc. Nasdaq ATHX 50 ORMD 50 Gynecological Oncologists 50 ISHLT 50 SU# [003] 50 metastatic renal cell carcinoma 50 transthyretin TTR mediated amyloidosis 50 HIF PHI 50 novel trazodone formulation 50 stent DES 50 omacetaxine mepesuccinate 50 number NCT# ClinicalTrials.gov 50 Vandetanib 50 LibiGel testosterone gel 50 Phase 2b study 50 Intervention Effectiveness 50 System Pharmacists 50 Oncology ESTRO 50 Orthopaedic Surgeons Annual Meeting 50 ixabepilone 50 Ceflatonin 50 Daclizumab 50 Human Brain Mapping 50 GASTRO 50 ZACTIMA 50 NCCN Clinical Practice 50 Management SCDM 50 Liver Meeting 50 HFSA Annual 50 website www.asco.org 50 REITWeek 50 Onconase 50 trials RCTs 50 Nasdaq SNSS 50 PRNewswire FirstCall Genaera 50 angiogenesis inhibitor 50 EXPAREL TM 50 Denufosol 50 Ophthalmic Plastic 50 Late Deafened Adults 50 Meets Primary Endpoint 50 VEITHsymposium 50 CIMZIA TM certolizumab pegol 50 Society Nephrology CJASN 50 heavily pretreated 50 Cardiovascular Therapeutics 50 thetreatment 50 DASISION 50 evaluating REVLIMID 50 catheter occlusion 50 sulodexide 50 Inc. Nasdaq AMLN 50 CLL8 50 anti angiogenic therapy 50 Plastic Surgeons ASPS 50 CALGB 50 prostate cancer HRPC 50 phase IIb trial 50 Reports Preclinical Data 50 Phase III placebo controlled 50 vinca alkaloid 50 Oligonucleotide Therapeutics Society 50 Lysosomal Disease Network 50 Society HIMSS 50 YONDELIS R 50 Inc. Nasdaq AVRX 50 Everolimus 50 Plant Biologists ASPB 50 Advanced Heart Failure 50 Printable slides 50 relapsing remitting MS RRMS 50 multicenter clinical 50 PROactive Study 50 tanespimycin 50 journal Arteriosclerosis Thrombosis 50 Acute Heart Failure 50 OTO EXPO 50 ENESTnd 50 resolvin 50 Onrigin 50 Urologic Oncology 50 Experimental NeuroTherapeutics 50 Pyridorin 50 Reolysin 50 Arch Intern Med 50 viral kinetic 50 Surgeons ACS 50 mg administered orally 50 RSNA 50 ProSavin 50 Bapineuzumab 50 Nasdaq SGMO announced 50 KRAS status 50 elacytarabine 50 Biomedical Optics 50 EURIDIS 50 Quinamed 50 Heart Assn 50 DAVANAT 50 PEARL HF 50 Presents Positive 50 Annual Institutional Investor 50 QLT# 50 CYT# 50 vorinostat 49 Gynecologic Oncology Group 49 Velcade bortezomib 49 Phase III VISTA 49 verteporfin 49 HDAC Inhibitor 49 ovarian suppression 49 PreCISe 49 Dacogen injection 49 Br J Cancer 49 xanthine oxidase inhibitor 49 vascular disrupting agents 49 pain palliation 49 Cardiology JACC 49 papillary renal cell carcinoma 49 Physical Anthropologists 49 Vaccine Immunology 49 Targanta Therapeutics Corporation 49 Lung Cancer IASLC 49 RIO Lipids 49 blinatumomab 49 PI3 kinase inhibitors 49 deforolimus 49 AAAAI Annual Meeting 49 Immunology AAAAI 49 lymphomas leukemias 49 Critical Care Medicine 49 Bipolar Disorders 49 Obesity NAASO 49 Gynecological Cancer 49 vivo efficacy 49 pemetrexed Alimta 49 Folfox 49 Pooled Analysis 49 rosuvastatin Crestor 49 HIMSS Annual 49 AAG geldanamycin analog 49 Biodefense Vaccines 49 PFO migraine 49 brivaracetam 49 Clinical Psychopharmacology 49 eltrombopag 49 clevidipine 49 Initiated Phase 49 CLARITY TIMI 49 Ophthalmic Drugs Advisory 49 CoFactor 49 phase IIb 49 J Natl Cancer Inst 49 Presents Preclinical Data 49 Experimental Hematology 49 trastuzumab DM1 49 randomized discontinuation trial 49 Phase IIB 49 IMiDs R 49 ESTRO 49 metastatic colorectal 49 Long Awaited Reality 49 Venous Forum 49 trastuzumab emtansine T DM1 49 Bioral ® 49 Alpharadin 49 recurrent glioblastoma multiforme 49 histone deacetylase HDAC 49 Therapeutic Targets 49 Tesmilifene 49 Keystone Symposia 49 Proxinium TM 49 BCIRG 49 Neulasta ® 49 Val HeFT 49 Hsp# inhibitor 49 multicenter Phase II 49 BioNumerik 49 anti arrhythmic drug 49 Fifth Decennial International 49 Tesetaxel 49 Forodesine HCl 49 SIR Spheres 49 Cambridge Healthtech Institute 49 Enzastaurin 49 LibiGel ® 49 NAREIT REITWeek 49 Inc. NASDAQ HEPH 49 th Annual Interscience 49 Nasdaq IDRA today 49 randomized multicenter trial 49 Neurological Societies 49 recurrent glioblastoma 49 olaparib 49 Immunotherapeutic 49 Telaprevir 49 Hormone Refractory Prostate Cancer 49 CYPHER R Sirolimus Eluting 49 Pediatric Otolaryngology 49 TMS Therapy 49 Peptide Symposium 49 eniluracil 49 Lung Transplantation ISHLT 49 Lipid Research 49 MEK inhibitors 49 motexafin gadolinium Injection 49 MEND CABG II 49 Mammalogists 49 Poster Presentation 49 ADVANCE PD